Top

Published in:

01-07-2022 | Chronic Lymphocytic Leukemia | News item

Duvelisib increases risk of serious AEs and death

Published in: Reactions Weekly | Issue 1/2022

Excerpt

The USA FDA is warning that 5-year survival results of the phase III DUO trial have shown that duvelisib [Copiktra] appears to increase the risk of death compared with the monoclonal antibody ofatumumab in patients with small lymphatic lymphoma or chronic lymphocytic leukaemia. The trial also found that duvelisib increased the risk of serious adverse events (AEs) including infections, diarrhoea, inflammatory bowel disease, pneumonitis, skin disorders and elevated liver enzymes. …

FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib) Internet Document : 6 Jul 2022. Available from: URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-possible-increased-risk-death-and-serious-side-effects-cancer-drug-copiktra

Title: Duvelisib increases risk of serious AEs and death
Publication date: 01-07-2022
Publisher: Springer International Publishing
Keywords: Chronic Lymphocytic Leukemia
Chronic Inflammatory Bowel Disease
Ofatumumab
Ofatumumab
Ofatumumab
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-19032-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Duvelisib increases risk of serious AEs and death

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Olanzapine

Methylphenidate

Chlorphenamine/dicycloverine/promethazine

Antiepileptic-drugs/antineoplastics/corticosteroids

Lamotrigine over dose

Pembrolizumab